This product is a proton pump inhibitor of gastric parietal cells. It can specifically inhibit the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, causing irreversible inhibition of the enzyme, thereby effectively inhibiting the secretion of gastric acid. It can not only non-competitively inhibit the gastric acid secretion caused by gastrin, histamine, and choline, but also inhibit some basic gastric acid secretion that is not affected by choline or H2 receptor blockers. This product is metabolized by the first system of the cytochrome P450 enzyme system in the liver cells, and can also be metabolized by the second system. It is not easy to have competitive effects of drug metabolism enzymes, reducing the interaction between drugs in the body. It has no mutagenic, carcinogenic and teratogenic effects.